RMD · Resmed Inc · Debt

Track RMD — free

$252.86 -0.20 (-0.08%) At close · Oct 23

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$36.48B

144.25M

Volume · Oct 23 1.03M Avg daily vol (3M) 1.32M

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Latest reported total

USD 660,000,000

As of Jun 30, 2026

Tracked instruments

Loans, facilities and note series

Annual baseline

Jun 30, 2026

Latest approved annual total

Reported total debt history

As of	Reported label	Amount	Source
2026-06-30	total outstanding debt	USD 660,000,000	10-K filed 2026-08-13 Our leverage and debt service obligations could adversely affect our business. As of June 30, 2026, our total outstanding debt was $660 million and we may incur additional indebtedness in the future. Our indebtedness could have adverse consequences, including:
2025-06-30	total consolidated debt	USD 700,000,000	10-K filed 2025-08-08 Our leverage and debt service obligations could adversely affect our business. As of June 30, 2025, our total consolidated debt was $0.7 billion and we may incur additional indebtedness in the future.
2024-06-30	total consolidated debt	USD 700,000,000	10-K filed 2024-08-09 Our leverage and debt service obligations could adversely affect our business. As of June 30, 2024, our total consolidated debt was $0.7 billion and we may incur additional indebtedness in the future.
2023-06-30	total consolidated debt	USD 1,400,000,000	10-K filed 2023-08-11 Our leverage and debt service obligations could adversely affect our business. As of June 30, 2023, our total consolidated debt was $1.4 billion and we may incur additional indebtedness in the future.
2022-06-30	our total consolidated debt	USD 800,000,000	10-K filed 2022-08-12 Our leverage and debt service obligations could adversely affect our business. As of June 30, 2022, our total consolidated debt was $0.8 billion and we may incur additional indebtedness in the future, including as a result of our pending acquisition of MEDIFOX DAN, which is expected to close during our fiscal year 2023.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Long-term debt, including current maturities	2026-06-30	USD 399,415,000	10-K filed 2026-08-13
Operating lease liabilities	2026-06-30	USD 166,554,000	10-K filed 2026-08-13
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 29,141,000 Noncurrent operating lease liabilities USD 137,413,000
Short-term borrowings	2026-06-30	USD 259,950,000	10-K filed 2026-08-13

9 filing observations remain unmatched and are excluded from instrument histories.

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

10 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 943819 CUSIP 761152107 13F (30d) 192 filings 187 filers Visit website Investor relations